These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30034942)

  • 1. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
    Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Vishwanatha JK; Mathew PA
    Am J Cancer Res; 2018; 8(6):1050-1063. PubMed ID: 30034942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.
    Mathew SO; Chaudhary P; Powers SB; Vishwanatha JK; Mathew PA
    Oncotarget; 2016 Oct; 7(42):68650-68661. PubMed ID: 27626681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer.
    Sun Y; Malaer JD; Mathew PA
    J Cancer Metastasis Treat; 2019; 2019(5):. PubMed ID: 34322598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking PCNA interaction with NKp44 enhances primary natural killer cell-mediated lysis of triple-negative breast cancer cells.
    Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Ahmed N; Vishwanatha JK; Mathew PA
    Am J Cancer Res; 2023; 13(3):1082-1090. PubMed ID: 37034219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer.
    Buller CW; Mathew PA; Mathew SO
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and Clinical Significance of Human NKRP1A/LLT1 Receptor/Ligand Interactions.
    Bialoszewska A; Malejczyk J
    Crit Rev Immunol; 2018; 38(6):479-489. PubMed ID: 31002602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection impairs NK cell functions
    Lenart M; Górecka M; Bochenek M; Barreto-Duran E; Szczepański A; Gałuszka-Bulaga A; Mazur-Panasiuk N; Węglarczyk K; Siwiec-Koźlik A; Korkosz M; Łabaj PP; Baj-Krzyworzeka M; Siedlar M; Pyrc K
    Front Immunol; 2023; 14():1123155. PubMed ID: 37287972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for LLT1 protein recognition by human CD161 protein (NKRP1A/KLRB1).
    Kamishikiryo J; Fukuhara H; Okabe Y; Kuroki K; Maenaka K
    J Biol Chem; 2011 Jul; 286(27):23823-30. PubMed ID: 21572041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-γ contributes to modulate immune responses.
    Germain C; Meier A; Jensen T; Knapnougel P; Poupon G; Lazzari A; Neisig A; Håkansson K; Dong T; Wagtmann N; Galsgaard ED; Spee P; Braud VM
    J Biol Chem; 2011 Nov; 286(44):37964-37975. PubMed ID: 21930700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of extracellular domain of human lectin-like transcript 1 (LLT1), the ligand for natural killer receptor-P1A.
    Kita S; Matsubara H; Kasai Y; Tamaoki T; Okabe Y; Fukuhara H; Kamishikiryo J; Krayukhina E; Uchiyama S; Ose T; Kuroki K; Maenaka K
    Eur J Immunol; 2015 Jun; 45(6):1605-13. PubMed ID: 25826155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lectin-Like Transcript 1 (LLT1) Checkpoint: A Novel Independent Prognostic Factor in HPV-Negative Oropharyngeal Squamous Cell Carcinoma.
    Sanchez-Canteli M; Hermida-Prado F; Sordo-Bahamonde C; Montoro-Jiménez I; Pozo-Agundo E; Allonca E; Vallina-Álvarez A; Álvarez-Marcos C; Gonzalez S; García-Pedrero JM; Rodrigo JP
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33255617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LLT1-CD161 Interaction in Cancer: Promises and Challenges.
    Braud VM; Meghraoui-Kheddar A; Elaldi R; Petti L; Germain C; Anjuère F
    Front Immunol; 2022; 13():847576. PubMed ID: 35185935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
    Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Role of NKR-P1A (CD161) and Lectin-like Transcript 1 in Natural Cytotoxicity against Human Articular Chondrocytes.
    Białoszewska A; Olkowska-Truchanowicz J; Bocian K; Osiecka-Iwan A; Czop A; Kieda C; Malejczyk J
    J Immunol; 2018 Jan; 200(2):715-724. PubMed ID: 29212911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells.
    Rosen DB; Cao W; Avery DT; Tangye SG; Liu YJ; Houchins JP; Lanier LL
    J Immunol; 2008 May; 180(10):6508-17. PubMed ID: 18453569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of LLT1 and PCNA as Natural Killer Cell Immune Evasion Strategies of HCT 116 Cells.
    Malaer JD; Mathew PA
    Anticancer Res; 2020 Dec; 40(12):6613-6621. PubMed ID: 33288556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LLT1-mediated activation of IFN-gamma production in human natural killer cells involves ERK signalling pathway.
    Bambard ND; Mathew SO; Mathew PA
    Scand J Immunol; 2010 Mar; 71(3):210-9. PubMed ID: 20415786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.
    Mandal T; Gnanasegaran S; Rodrigues G; Kashipathi S; Tiwari A; Dubey AK; Bhattacharjee S; Manjunath Y; Krishna S; Madhusudhan MS; Ghosh M
    BMC Cancer; 2024 Nov; 24(1):1365. PubMed ID: 39511540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.